Myr­iad launches hered­i­tary cancer de­tec­tion tool

BioSpectrum (India) - - WORLD NEWS -

US-based molec­u­lar di­ag­nos­tics firm Myr­iad Ge­net­ics has in­tro­duced a new med­i­cal tool, risk Score, to sup­port its my Risk test devel­oped for hered­i­tary cancer. risk Score is an al­go­rithm designed to com­bine ge­netic mark­ers with a pa­tient’s fam­ily and clin­i­cal his­tory to quan­tify the risk of breast cancer de­vel­op­ment. The tool will com­bine data from more than 80 ge­netic mark­ers called sin­gle nu­cleo­tide poly­mor­phisms (SNPs) through­out the genome with a fam­ily and per­sonal his­tory al­go­rithm called Tyrer-Cuz­ick model. The Myr­iad my Risk Hered­i­tary Cancer test is a 28-gene panel that can iden­tify the risk of breast, ovar­ian, gas­tric, col­orec­tal, pan­cre­atic, melanoma, prostate and en­dome­trial can­cers. In ad­di­tion to a risk as­sess­ment, the sim­ple and easy-to-use test de­liv­ers spe­cific med­i­cal man­age­ment rec­om­men­da­tions to pa­tients who test ei­ther pos­i­tive or neg­a­tive ac­cord­ing to the guide­lines of se­lect pro­fes­sional med­i­cal so­ci­eties.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.